Navigation Links
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
Date:5/14/2008

BRISBANE, Australia, May 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX:PGL; Nasdaq: PGLA) today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047) for patients with advanced cancer.

Progen has commenced development of PG-11047 - the lead clinical compound in the Company's polyamine program - following its acquisition of Cellgate, Inc earlier this year. The first patient to be recruited into the trial re-initiation has been enrolled at the University of Chicago.

The trial is exploring the potential of PG-11047 as a single anti-cancer agent and is designed to assess the agent's maximum tolerated dose. Under CellGate, the trial had recruited 31 patients and had shown little evidence of toxicity, while using significantly higher doses than most previous studies of polyamine compounds.

Justus Homburg, Progen's CEO, said, "Since the acquisition of CellGate, we have been assessing our portfolio of clinical and pre-clinical compounds in order to determine which to drive forward. Our re-initiation of PG-11047 in phase 1 clinical development is the first step in driving potential value from our expanded portfolio of first-in-class oncology therapies."

Data from the trial will be used in parallel with a separate PG-11047 study assessing the agent in combination with other marketed anti-cancer drugs as the basis for determining potential phase 2 development. Progen expects the study to produce data within the next 12 months.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

About PG-11047: PG-11047 is a polyamine analogue which modifies the production of natural polyamines. Polyamines are a class of chemical which are involved in regulation of cell growth. They are overproduced in many cancers, and PG-11047 is believed to restore polyamine reduction to natural levels. Despite being the focus of scientific interest for many years, this mechanism is unique, and if successful, PG-11047 could become a first-in-class oncology product. To date, PG-11047 has been shown to have anti-tumor activity in animal models, combined with a good safety profile.

Progen Information:

Justus Homburg, CEO

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Media and Investor Relations:

Cindy Ingram, Investor Relations Manager

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: cindyi@progen-pharma.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
3. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. Progen Announces PI-88 Phase 2 Lung Cancer Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
11. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... , M.D., Ph.D., as President and Chief Executive Officer (CEO) ... 2017. Dr. Craig succeeds Richard Love , interim President ... Board of Directors.  Dr. Craig has over 20 years of ... US and Europe . "On ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... This ... laser diffraction analysis as a tool to characterize particle size distributions in the ... obtain improved results and novel scientific findings. It describes methods of optimized and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... new informational post on robotic hair transplantation. San Francisco residents may be confused ... Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be used to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ARLINGTON, VA (PRWEB) , ... February 26, 2017 , ... ... Medicaid Managed Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, ... work with PerformCARE to use behavioral health analytics to improve Medicaid population health management. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
Breaking Medicine News(10 mins):